Physician profile
Gowda Sharath
NPI 1043466576
$1,176.16
in general payments reported to CMS, 2019-2025
15 companies · $70.93 in 2025
The $70.93 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $134 · 2021: $46.57 · 2022: $322 · 2023: $221 · 2024: $277 · 2025: $70.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $364.87 | 2019-2024 | Xarelto |
| Pfizer INC. | $210.64 | 2020-2025 | |
| Abbvie INC. | $196.28 | 2022-2024 | Dalvance, Avycaz |
| E.R. Squibb & Sons, L.L.C. | $86.82 | 2021-2023 | Camzyos |
| Vapotherm INC | $63.84 | 2019 | |
| Merck Sharp & Dohme LLC | $50.65 | 2021-2024 | Vaxneuvance, Capvaxive |
| Novo Nordisk INC | $32.38 | 2024-2025 | Ozempic, Rybelsus |
| Axsome Therapeutics, INC. | $31.72 | 2024 | Auvelity |
| Dexcom, INC. | $31.60 | 2023-2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $27.42 | 2022-2024 | Veklury |
| Terumo Medical Corporation | $19.61 | 2025 | Glidesheath Slender |
| Novartis Pharmaceuticals Corporation | $16.64 | 2021 | |
| Glaxosmithkline, LLC. | $15.34 | 2024 | Bexsero, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $15.02 | 2024 | Voquezna |
| Allergan, INC. | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gowda Sharath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.